US20030114503A1
(en)
*
|
1997-06-16 |
2003-06-19 |
Pfizer Inc. |
Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the treatment of cancer
|
ID27199A
(id)
*
|
1998-07-06 |
2001-03-08 |
Janssen Pharmaceutica Nv |
Penghambat transferase protein farnesil untuk pengobatan artropatis
|
JP3494409B2
(ja)
*
|
1998-08-27 |
2004-02-09 |
ファイザー・プロダクツ・インク |
抗がん剤として有用なアルキニル置換キノリン−2−オン誘導体
|
SK2442001A3
(en)
*
|
1998-08-27 |
2002-10-08 |
Pfizer Prod Inc |
Alkynyl-substituted quinolin-2-ones, pharmaceutical compositions, their use in the treatment and method for producing thereof
|
TR200201297T2
(tr)
|
1999-02-11 |
2002-06-21 |
Pfizer Products Inc. |
Antikanser maddeleri olarak faydalı heteroaril-ikame edilmiş kinolin-2-on türevleri.
|
HN2000000266A
(es)
|
2000-01-21 |
2001-05-21 |
Pfizer Prod Inc |
Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
|
EP1267848B1
(en)
|
2000-02-24 |
2007-10-17 |
Janssen Pharmaceutica N.V. |
Dosing regimen comprising a farnesyl protein transferase inhibitor for the treatment of cancer
|
JO2361B1
(en)
|
2000-06-22 |
2006-12-12 |
جانسين فارماسيوتيكا ان. في |
Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl
|
US7173040B2
(en)
|
2000-09-25 |
2007-02-06 |
Janssen Pharmaceutica N.V. |
Farnesyl transferase inhibiting 6-[(substituted phenyl)methyl]-quinoline and quinazoline derinazoline derivatives
|
JP4974439B2
(ja)
*
|
2000-09-25 |
2012-07-11 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
ファルネシルトランスフェラーゼを阻害する6−ヘテロシクリルメチルキノリノン誘導体
|
AU2002220559A1
(en)
|
2000-09-25 |
2002-04-02 |
Janssen Pharmaceutica N.V. |
Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives
|
EP1322635B1
(en)
|
2000-09-25 |
2006-03-22 |
Janssen Pharmaceutica N.V. |
Farnesyl transferase inhibiting quinoline and quinazoline derivatives as farnesyl transferase inhibitors
|
DE60139080D1
(de)
|
2000-11-21 |
2009-08-06 |
Janssen Pharmaceutica Nv |
Farnesyltransferase hemmende benzoheterocyclische derivate
|
MXPA03005525A
(es)
*
|
2000-12-19 |
2003-10-06 |
Pfizer Prod Inc |
Formas cristalinas de sales de 2,3-dihidroxibutanodioato de 6-[(4-cloro -fenil)- hidroxi-(3 -metil-3h-imidazol -4-il)-metil] -4-(3-etinil-fenil) -1-metil-1h -quinolein-2 -ona, y metodo de produccion.
|
US7129356B2
(en)
|
2000-12-27 |
2006-10-31 |
Janssen Pharmaceutica N.V. |
Farnesyl transferase inhibiting 4-substituted quinoline and quinazoline derivatives
|
AU2002236813A1
(en)
*
|
2001-01-22 |
2002-07-30 |
Schering Corporation |
Treatment of malaria with farnesyl protein transferase inhibitors
|
DK1373255T3
(da)
*
|
2001-03-12 |
2005-05-23 |
Janssen Pharmaceutica Nv |
Fremgangsmåde til fremstilling af imidazolforbindelser
|
US20020151563A1
(en)
*
|
2001-03-29 |
2002-10-17 |
Pfizer Inc. |
Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the inhibition of abnormal cell growth
|
WO2002080895A2
(en)
*
|
2001-04-06 |
2002-10-17 |
Schering Corporation |
Treatment of malaria with farsenyl protein transferase inhibitors
|
WO2002098425A1
(en)
*
|
2001-06-04 |
2002-12-12 |
Cytovia, Inc. |
Substituted 4-aryl-3-(3-aryl-1-oxo-2-propenyl)-2(1h)-quinolinones and analogs as activators of caspases and inducers of apoptosis and the use thereof
|
EP1408971A4
(en)
|
2001-06-21 |
2006-01-25 |
Ariad Pharma Inc |
NEW QUINOLINES AND THEIR USES
|
US6740757B2
(en)
*
|
2001-08-29 |
2004-05-25 |
Pfizer Inc |
Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1h-quinolin-2-one and salts thereof, useful in the treatment of cancer
|
WO2003051880A1
(en)
|
2001-12-19 |
2003-06-26 |
Janssen Pharmaceutica N.V. |
1,8-annelated quinoline derivatives substituted with carbon-linked triazoles as farnesyl transferase inhibitors
|
ES2287466T3
(es)
|
2002-03-22 |
2007-12-16 |
Janssen Pharmaceutica N.V. |
Derivados de 2-quinolinona y quinazolina de bencilimidazolil sustituidas como inhibidores de la farnesil transferasa.
|
ATE336496T1
(de)
|
2002-04-15 |
2006-09-15 |
Janssen Pharmaceutica Nv |
Farnesyl transferase hemmende tricyclische quinazolinederivate substitutiert mit kohlenstoff-gebundenen imidazolen oder triazolen
|
EA008501B1
(ru)
*
|
2002-12-19 |
2007-06-29 |
Пфайзер Инк. |
2-(1н-индазол-6-иламино)бензамидные соединения как ингибиторы протеинкиназ, полезные для лечения офтальмологических заболеваний
|
JP4691041B2
(ja)
|
2003-11-20 |
2011-06-01 |
チルドレンズ ホスピタル メディカル センター |
Gtpアーゼ阻害剤および使用方法
|
WO2005089515A2
(en)
*
|
2004-03-18 |
2005-09-29 |
The Brigham And Women's Hospital, Inc. |
Methods for the treatment of synucleinopathies
|
BRPI0509580A
(pt)
*
|
2004-03-30 |
2007-11-27 |
Pfizer Prod Inc |
combinações de inibidores de transdução de sinal
|
EP1786777A1
(en)
*
|
2004-08-26 |
2007-05-23 |
Pfizer, Inc. |
Aminoheteroaryl compounds as protein tyrosine kinase inhibitors
|
KR100859891B1
(ko)
*
|
2004-08-26 |
2008-09-23 |
화이자 인코포레이티드 |
단백질 키나제 억제제로서 거울상이성질체적으로 순수한아미노헤테로아릴 화합물
|
ES2355923T3
(es)
*
|
2004-08-26 |
2011-04-01 |
Pfizer, Inc. |
Compuestos de aminoheteroarilo sustituidos con pirazol como inhibidores de proteina quinasa.
|
DK2362218T3
(en)
|
2004-11-05 |
2014-11-17 |
Janssen Pharmaceutica Nv |
Methods for monitoring the effectiveness of farnesyl transferase
|
US20060107555A1
(en)
*
|
2004-11-09 |
2006-05-25 |
Curtis Marc D |
Universal snow plow adapter
|
US20060281788A1
(en)
|
2005-06-10 |
2006-12-14 |
Baumann Christian A |
Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
|
CA2617056A1
(en)
|
2005-07-29 |
2007-02-08 |
Children's Hospital Medical Center |
Gtpase inhibitors and methods of use and crystal structure of rac-1 gtpase
|
PE20080035A1
(es)
|
2005-09-07 |
2008-01-30 |
Amgen Fremont Inc |
Anticuerpos monoclonales humanos para la quinasa-1 tipo receptor de activina
|
DK1926996T3
(da)
|
2005-09-20 |
2012-01-23 |
Osi Pharmaceuticals Llc |
Biologiske markører, som er prædiktive for anti-cancer-reaktion på insulinlignende vækstfaktor-1-receptorkinasehæmmere
|
WO2007075923A2
(en)
|
2005-12-23 |
2007-07-05 |
Link Medicine Corporation |
Treatment of synucleinopathies
|
TW200812615A
(en)
|
2006-03-22 |
2008-03-16 |
Hoffmann La Roche |
Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
|
US8697716B2
(en)
|
2006-04-20 |
2014-04-15 |
Janssen Pharmaceutica Nv |
Method of inhibiting C-KIT kinase
|
ATE510832T1
(de)
|
2006-04-20 |
2011-06-15 |
Janssen Pharmaceutica Nv |
Heterocyclische verbindungen als c-fms- kinasehemmer
|
BRPI0710548B8
(pt)
|
2006-04-20 |
2021-05-25 |
Janssen Pharmaceutica Nv |
inibidores de c-fms cinase, composição farmacêutica e forma de dosagem farmacêutica
|
AU2007251282A1
(en)
|
2006-05-09 |
2007-11-22 |
Pfizer Products Inc. |
Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
|
NZ574580A
(en)
|
2006-08-21 |
2011-12-22 |
Hoffmann La Roche |
Her2 tumor therapy with an anti-vegf antibody
|
WO2008112525A2
(en)
*
|
2007-03-09 |
2008-09-18 |
Link Medicine Corporation |
Treatment of lysosomal storage diseases
|
JO3240B1
(ar)
|
2007-10-17 |
2018-03-08 |
Janssen Pharmaceutica Nv |
c-fms مثبطات كيناز
|
WO2009151683A2
(en)
|
2008-03-12 |
2009-12-17 |
Link Medicine Corporation |
Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
|
DE102008022221A1
(de)
*
|
2008-05-06 |
2009-11-12 |
Universität des Saarlandes |
Inhibitoren der humanen Aldosteronsynthase CYP11B2
|
US20100331363A1
(en)
*
|
2008-11-13 |
2010-12-30 |
Link Medicine Corporation |
Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
|
AU2009313927A1
(en)
|
2008-11-13 |
2010-05-20 |
Astrazeneca Ab |
Azaquinolinone derivatives and uses thereof
|
US20110060005A1
(en)
*
|
2008-11-13 |
2011-03-10 |
Link Medicine Corporation |
Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
|
WO2010099139A2
(en)
|
2009-02-25 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Combination anti-cancer therapy
|
EP2400990A2
(en)
|
2009-02-26 |
2012-01-04 |
OSI Pharmaceuticals, LLC |
In situ methods for monitoring the emt status of tumor cells in vivo
|
WO2010099138A2
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
WO2010099364A2
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
EP2401614A1
(en)
|
2009-02-27 |
2012-01-04 |
OSI Pharmaceuticals, LLC |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
US20110275644A1
(en)
|
2010-03-03 |
2011-11-10 |
Buck Elizabeth A |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
EP2542893A2
(en)
|
2010-03-03 |
2013-01-09 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
US20120214830A1
(en)
|
2011-02-22 |
2012-08-23 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
|
WO2012149014A1
(en)
|
2011-04-25 |
2012-11-01 |
OSI Pharmaceuticals, LLC |
Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
|
WO2013152252A1
(en)
|
2012-04-06 |
2013-10-10 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
WO2013166043A1
(en)
|
2012-05-02 |
2013-11-07 |
Children's Hospital Medical Center |
Rejuvenation of precursor cells
|
AU2013299922B2
(en)
|
2012-08-07 |
2018-06-21 |
Janssen Pharmaceutica Nv |
Process for the preparation of heterocyclic ester derivatives
|
JOP20180012A1
(ar)
|
2012-08-07 |
2019-01-30 |
Janssen Pharmaceutica Nv |
عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
|
AR094403A1
(es)
|
2013-01-11 |
2015-07-29 |
Hoffmann La Roche |
Terapia de combinación de anticuerpos anti-her3
|
US10028503B2
(en)
|
2014-06-18 |
2018-07-24 |
Children's Hospital Medical Center |
Platelet storage methods and compositions for same
|
PT3640345T
(pt)
|
2015-08-17 |
2021-12-29 |
Kura Oncology Inc |
Métodos de tratamento de doentes com cancro usando inibidores da farnesiltransferase
|
CN108601752A
(zh)
|
2015-12-03 |
2018-09-28 |
安吉奥斯医药品有限公司 |
用于治疗mtap缺失型癌症的mat2a抑制剂
|
US20190119758A1
(en)
|
2016-04-22 |
2019-04-25 |
Kura Oncology, Inc. |
Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors
|
DK3534885T3
(da)
|
2016-11-03 |
2021-04-12 |
Kura Oncology Inc |
Farnesyltransferase-inhibitorer til anvendelse i behandling af kræft
|
US11471538B2
(en)
|
2017-02-10 |
2022-10-18 |
INSERM (Institut National de la Santéet de la Recherche Medicale) |
Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the MAPK pathway
|
US10137121B2
(en)
|
2017-02-21 |
2018-11-27 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
EP3432883B1
(en)
|
2017-02-21 |
2021-07-28 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
US10806730B2
(en)
|
2017-08-07 |
2020-10-20 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
MY200746A
(en)
|
2017-08-07 |
2024-01-13 |
Kura Oncology Inc |
Methods of treating cancer with farnesyltransferase inhibitors
|
WO2019113269A1
(en)
|
2017-12-08 |
2019-06-13 |
Kura Oncology, Inc. |
Methods of treating cancer patients with farnesyltransferase inhibitors
|
CA3117968A1
(en)
|
2018-11-01 |
2020-05-07 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
CA3124616A1
(en)
|
2018-12-21 |
2020-06-25 |
Kura Oncology, Inc. |
Therapies for squamous cell carcinomas
|
US20220142983A1
(en)
|
2019-03-01 |
2022-05-12 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
WO2020190604A1
(en)
|
2019-03-15 |
2020-09-24 |
Kura Oncology, Inc. |
Methods of treating cancer patients with farnesyltransferase inhibitors
|
CN113795253A
(zh)
|
2019-03-29 |
2021-12-14 |
库拉肿瘤学公司 |
用法呢基转移酶抑制剂治疗鳞状细胞癌的方法
|
TW202102218A
(zh)
|
2019-04-01 |
2021-01-16 |
美商庫拉腫瘤技術股份有限公司 |
以法呢基(farnesyl)轉移酶抑制劑治療癌症的方法
|
US20220305001A1
(en)
|
2019-05-02 |
2022-09-29 |
Kura Oncology, Inc. |
Methods of treating acute myeloid leukemia with farnesyltransferase inhibitors
|
WO2021155006A1
(en)
|
2020-01-31 |
2021-08-05 |
Les Laboratoires Servier Sas |
Inhibitors of cyclin-dependent kinases and uses thereof
|